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As the only marketed drug that is capable of clearing
mature P. falciparum gametocytes, primaquine offers a
unique ability to stop malaria transmission from humans
to mosquitoes. Despite its potential role in malaria control
and elimination, the widespread adoption of primaquine
has been slow due to its ability to induce hemolysis in
G6PD-deficient individuals. While hemolysis is understood
to be dose dependent, there are limited data to support the
safety and efficacy of current WHO recommendation to
give, in conjunction with an artemisinin-based combination
therapy, single low-dose primaquine (0.25 mg/kg) to all
parasitologically-confirmed P. falciparum cases in areas
threatened by artemisinin resistance or in settings
approaching elimination.
In March 2012, a group of experts from academia,
industry, non-governmental organizations, malaria pro-
grams, and funders convened to discuss existing data on
the use of primaquine as a malaria transmission blocker.
The meeting served to identify roadblocks and to propose
a roadmap to establish whether low-dose primaquine can
be safely and effectively deployed to block P. falciparum
malaria transmission in sub-Saharan Africa [1].
Since then, much knowledge has been gained on the
pharmacokinetics, safety and efficacy of low-dose prima-
quine. Regulatory barriers to the supply and manufacture
of low-dose primaquine in Africa have also been investi-
gated. In March 2014, the group of experts reconvened to
discuss roadmap progress and update potential knowledge
gaps that need to be addressed in order to determine if
and how low-dose primaquine can be implemented as a
malaria transmission blocker. We will provide roadmap
updates based on the latest meeting and will highlight
gaps to welcome discussion and advice from the malaria
research community.
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